Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$3.89 - $8.57 $3.62 Million - $7.96 Million
929,316 New
929,316 $4.01 Million
Q1 2022

May 10, 2022

SELL
$8.6 - $15.48 $258,000 - $464,400
-30,000 Closed
0 $0
Q3 2021

Nov 12, 2021

BUY
$17.43 - $24.34 $522,900 - $730,200
30,000 New
30,000 $637,000

Others Institutions Holding ERAS

About Erasca, Inc.


  • Ticker ERAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 122,147,000
  • Market Cap $299M
  • Description
  • Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...
More about ERAS
Track This Portfolio

Track Ghisallo Capital Management LLC Portfolio

Follow Ghisallo Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ghisallo Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ghisallo Capital Management LLC with notifications on news.